Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss ⊖
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
CagriSema
since
auto-detected in 11 stories
4 months ago
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades ⊖
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
5 months ago
Novo Nordisk shares tumble after company forecasts sales declines this year ⊕
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
15 months ago
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ○
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ○
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure ○
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.
16 months ago
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug ○
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug ○
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug ○
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
17 months ago
Trump fears drive gold to record high, as yuan hit by US-China trade war – business live ○
found
a story from The Guardian ⚠️ › International
Rolling coverage of the latest economic and financial news
Novo Nordisk has reported better-than-expected revenues, with sales of its Wegovy obesity drug surging by 86% last year, but expects growth t…